Cell-based therapies, angiogenesis, and gene transfer offer promising experimental avenues for cardiac repair in ischemic heart disease, though significant clinical and safety hurdles remain.
Cell-based interventions, angiogenesis and gene therapy are among the newest treatment modalities that have been proposed to improve outcomes in patients with ischaemic heart disease. Experimental data have established that implantation of contractile cells into fibrous post-infarction scars can allow those tissues to regain some functionality. Although clinical data are still preliminary, they support the concept of cell transplantation and raise realistic hopes that it will find a place among strategies to ameliorate heart failure in the future. Therapeutic angiogenesis is another promising means of ameliorating ischaemic symptoms as there is already experimental evidence that angiogenic growth factors can stimulate the development of functionally significant new blood supply. In addition, successful correction of major abnormalities of calcium cycling by adenoviral gene transfer represents an encouraging finding in gene therapy. However, the complexity of gene dysregulation that is involved in heart failure complicates identification of the culprit genes, and important safety issues remain to be addressed before such therapies may proceed to clinical trials.
No takes yet. Share an insight, caveat, or question.
MENASCHE et al. (2002) conducted a review in Ischaemic heart disease and heart failure. Cell-based interventions, angiogenesis, and gene therapy was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: